Comparison Study of E-cadherin Expression in Primary Breast Cancer and its Corresponding Metastatic Lymph Node
Liesheng L, Lei Y, Zhenshun S, Lijun Z, Donglei Z* and Zhen Y
Department of General Surgery, Tenth People’s Hospital of Shanghai Tongji University, Shanghai, PR China
- *Corresponding Author:
- Donglei Z
Department of General Surgery
Tenth People’s Hospital of Shanghai Tongji University
Shanghai, PR China
Tel: 86-21-63240090 ext. 3112
E-mail: [email protected]
Received Date: March 07, 2014; Accepted Date: May 23, 2014; Published Date: May 25, 2014
Citation: Liesheng L, Lei Y, Zhenshun S, Lijun Z, Donglei Z et al. (2014) Comparison Study of E-cadherin Expression in Primary Breast Cancer and its Corresponding Metastatic Lymph Node. J Cytol Histol 5:248. doi: 10.4172/2157-7099.1000248
Copyright: © 2014 Liesheng L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Introduction: E-cadherin is an intercellular adhesion molecule, whose loss of expression may facilitate the process of cancer invasion and metastasis. Although the expression of E-cadherin has been widely studied in primary breast cancers, little is known about its expression at the corresponding metastatic lymph node. Here we comparatively studied their E-cadherin expression patterns and related them to the pathological data of breast cancer patients.
Methods: Only lymph nodes which were pathologically identified as metastases were included in this study to pair up the primary tumors. The quantitative real-time PCR (Q-RT-PCR) technique was used to assess the Ecadherin RNA expression levels in invasive ductal breast cancer subjects. E-cadherin gene copies were normalized using beta-actin gene copies. ER, PR, cerbB2 expressions in the primary tumor were routinely examined by immunohistochemistry method. Tumor characteristics and number of metastatic lymph nodes were gathered from the pathology reports.
Results: We tried to explore the relationship between E-cadherin expression in 21 primary tumors and their corresponding metastatic lymph nodes. However, the Q-RT-PCR data shows that an aberrant expression exists in both primary tumors and the corresponding lymph nodes (p=0.115), in which metastatic lymph nodes showed slight higher gene copies comparing to primary sites (77.77 ± 94.74vs43.35 ± 40.03, respectively). It is noteworthy that nodal E-cadherin expression was closely but negatively correlated with tumor size (p<0.01, r= -0.775) and number of meta sized lymph nodes (p<0.05, r=- 0.519), as tumor size and number of metastasized lymph nodes were already clinically proven to be important prognostic factors. There was no correlation between ER, PR, cerbB2 status in primary tumors and the nodal E-cadherin expression (p>0.05).
Conclusions: These study shows that E-cadherin expression is aberrant in invasive ductal cancers and their corresponding metastatic lymph nodes. E-cadherin expression in the metastasized lymph node is closely related to tumor size and number of metastasized lymph nodes.